Robert Lanza

Worldwide Regenerative Medicine Industry to 2025 - Featuring Allergan, Amgen and Baxter International Among Others

Retrieved on: 
Monday, November 9, 2020
Branches of biology, Biology, Regenerative biomedicine, Emerging technologies, Life sciences, Regenerative medicine, Tissue engineering, Regeneration, Stem cells, National Center for Regenerative Medicine, Robert Lanza

Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs.

Key Points: 
  • Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs.
  • Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies.
  • Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.
  • What is the structure of the global regenerative medicine market and who are the key players?

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

Retrieved on: 
Thursday, October 1, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Emerging technologies, Bioethics, Gene therapy, Cell therapy, Robert Lanza

More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products.

Key Points: 
  • More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products.
  • He answered the rhetorical question that was the title of his talk "How can we outsource stem cell clinical trials without counting tissue stem cells?"
  • He described how tissue stem cell counting technologies represented advantages both for discovery of novel drugs and for toxicology evaluations of new drug candidates.
  • Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Asymmetrex Presents Benefits of Stem Cell Counting at Clinical Trial Supply Conference

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Emerging technologies, Stem cell research, Life extension, Stem-cell therapy, Gene therapy, Embryonic stem cell, Robert Lanza

BOSTON, May 13, 2020 /PRNewswire-PRWeb/ --On May 12, the director of stem cell biotechnology company Asymmetrex continued to demonstrate the reach of his company's tissue stem cell counting technology into all aspects of the stem cell regenerative medicine industry.

Key Points: 
  • BOSTON, May 13, 2020 /PRNewswire-PRWeb/ --On May 12, the director of stem cell biotechnology company Asymmetrex continued to demonstrate the reach of his company's tissue stem cell counting technology into all aspects of the stem cell regenerative medicine industry.
  • Speaking online in Arena International's Clinical Trial Supply 2020 conference , James Sherley, M.D., Ph.D. outlined how achieving a more effective supply chain for stem-gene therapy clinical trials will require the industry to advance to certification of the stem cell-specific properties of transported cell and gene therapies.
  • In his clinical trial supply presentation, he related the importance of the same care in ensuring that the potency and quality of stem cell treatments are preserved during transport for supply of stem-gene clinical trials.
  • Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations.

New Mouse Models of Retinal Degeneration Enable Transplantation of Retinal Sheets Derived from Human Embryonic Stem Cells

Retrieved on: 
Wednesday, May 16, 2018
Biology, Stem cells, Induced stem cells, Biotechnology, Regenerative biomedicine, Developmental biology, Induced pluripotent stem cell, Embryonic stem cell, Retina, Robert Lanza

A promising therapeutic option for the treatment of retina degeneration consists of transplanting retinal tissue derived from embryonic or induced pluripotent stem cells (ES/IPS cells).

Key Points: 
  • A promising therapeutic option for the treatment of retina degeneration consists of transplanting retinal tissue derived from embryonic or induced pluripotent stem cells (ES/IPS cells).
  • It is known that photoreceptor precursor cells derived from embryonic stem cells can be transplanted in adult mouse models of retinal degeneration that still have dysfunctional photoreceptor layer (or outer nuclear layer).
  • However, transplanting retina sheets derived from human embryonic stem cells in rodent models is challenging and often results in rejection and in the transplanted cells not maturing properly.
  • Thus, immunodeficient end-stage retinal degeneration mouse models without any outer nuclear layer structure are important for preclinical studies investigating the feasibility of transplantation of tissues derived from human embryonic stem cells or induced pluripotent stem cells.